Nasdaq Surges Over 150 Points; ConocoPhillips Earnings Top Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Source: Benzinga
U.S. Stock Market Overview: U.S. stocks showed mixed results with the Nasdaq gaining over 150 points, while the Dow slightly declined. Notable movements included ConocoPhillips reporting better-than-expected earnings and significant gains for CIMG Inc. and Brilliant Earth Group, while Sabre Corporation and Sana Biotechnology saw substantial declines.
Global Market Trends: European and Asian markets mostly closed higher, with the eurozone's STOXX 600 rising by 0.8% and Japan's Nikkei 225 gaining 0.65%. Additionally, U.S. economic indicators showed a slight increase in wholesale inventories and a rise in initial jobless claims.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SANA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SANA
Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.600
Low
7.00
Averages
8.00
High
9.00
Current: 4.600
Low
7.00
Averages
8.00
High
9.00
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sana Biotechnology to Present Business Update at 44th J.P. Morgan Healthcare Conference
- Conference Timing: Sana Biotechnology will webcast its presentation at 9:45 a.m. PT on January 14, 2026, aiming to enhance investor understanding of the company's strategic direction through a comprehensive business overview.
- Executive Participation: CEO Steve Harr will lead the presentation, showcasing the latest research advancements in gene repair and cell replacement, which will further elevate the company's influence in the biotechnology sector.
- Webcast Accessibility: The webcast will be available on Sana's Investor Relations page and will include a replay for 30 days post-conference, ensuring investors can access critical information at their convenience.
- Vision Statement: Sana Biotechnology focuses on transforming patient treatment through engineered cells, emphasizing its innovative capabilities in gene repair and cell replacement, which aims to attract more investor interest in its long-term growth potential.
Continue Reading
Sana Biotechnology Achieves Potent Gene Editing in Murine Models Using Fusogen Technology
- Technological Breakthrough: Sana's Fusogen technology has achieved potent gene editing of hematopoietic stem cells in murine models, demonstrating stable editing capabilities in the bone marrow, which could transform treatments for diseases like sickle cell disease and beta thalassemia.
- Enhanced Delivery Efficiency: The use of systemically delivered virus-like particles (VLPs) with this technology avoids off-target delivery to hepatocytes, significantly improving the specificity and efficiency of gene editing while reducing side effects during treatment.
- Clinical Application Prospects: Sana plans to file an IND for SG293 by 2027, targeting B-cell cancers and autoimmune diseases, showcasing the broad application potential of Fusogen technology in treating various conditions.
- Strategic Implications: The findings not only expand the application scope of Fusogen technology but also simplify the supply chain and reduce reliance on high-dose chemotherapy, thereby lowering the risks of infections and secondary cancers for patients.
Continue Reading